What is the lowest available dose of Cymbalta (duloxetine) and the typical starting dose for adult patients?

Lowest Available Dose of Cymbalta (Duloxetine)

The lowest commercially available dose of Cymbalta is 20 mg, though this is below the therapeutic range for all FDA-approved indications; the recommended starting dose is 30 mg once daily for one week, followed by escalation to the target therapeutic dose of 60 mg once daily. 1, 2

Available Dosage Strengths

• Duloxetine delayed-release capsules are manufactured in 20 mg, 30 mg, 40 mg, and 60 mg strengths. 2
• The 20 mg capsule exists primarily to facilitate tapering during discontinuation, not as an initial therapeutic dose. 1

Standard Starting Dose for Adults

For most indications, begin duloxetine at 30 mg once daily for 1 week before increasing to 60 mg once daily. 1, 2

• This initial week at 30 mg significantly reduces treatment-emergent nausea—the most common adverse effect—while producing only a transient delay in therapeutic effect compared to starting directly at 60 mg daily. 1
• The 30 mg starting dose allows patients to adjust to the medication before reaching the therapeutic dose. 1

Indication-Specific Starting Doses

• Major depressive disorder, generalized anxiety disorder, fibromyalgia, chronic musculoskeletal pain (including osteoarthritis and chronic low back pain): Start 30 mg once daily × 1 week → increase to 60 mg once daily. 1, 2
• Diabetic peripheral neuropathic pain: The FDA label states 60 mg once daily is the standard dose, though "for patients for whom tolerability is a concern, a lower starting dose may be considered." 2
• Chemotherapy-induced peripheral neuropathy: Start 30 mg daily × 1 week → increase to 60 mg daily. 1

Special Populations

Geriatric Patients (≥65 Years)

In patients aged 65 years or older, start duloxetine at 30 mg once daily for at least 2 weeks before considering an increase to the target dose of 60 mg daily. 1, 2

• Subsequent titration should be done in 30 mg increments with a minimum of 1 week at each dose level. 1
• This slower titration strategy enhances tolerability and safety across all indications in older adults. 1
• Older adults are more prone to severe adverse events, including cognitive impairment, falls, and drug-drug interactions related to polypharmacy. 3

Pediatric Patients (7–17 Years) with Generalized Anxiety Disorder

• Initiate at 30 mg once daily × 2 weeks before considering an increase to 60 mg once daily. 2
• The recommended dosage range is 30–60 mg once daily; some patients may benefit from doses above 60 mg once daily. 2
• If escalating beyond 60 mg, increase in 30 mg increments; the maximum studied dose is 120 mg per day. 2

Patients with Renal or Hepatic Impairment

• Severe renal impairment (creatinine clearance <30 mL/min): Avoid duloxetine use. 1, 2
• Chronic liver disease or cirrhosis: Avoid duloxetine use. 2
• Mild to moderate renal impairment: Consider a lower starting dose (30 mg daily) and gradual increase. 1

Target Therapeutic Dose

• 60 mg once daily is the target maintenance dose for most indications, demonstrating consistent efficacy across depression, anxiety, and multiple pain conditions. 1, 3
• Approximately 50% of patients achieve at least 50% pain reduction at 12 weeks with 60 mg daily for diabetic peripheral neuropathy. 3
• Most patients achieve adequate response by 4–6 weeks at 60 mg daily. 4

Maximum Approved Dose

The highest recommended dose is 120 mg per day (administered as 60 mg twice daily). 1, 2

• In diabetic peripheral neuropathy, 120 mg daily achieved a number-needed-to-treat (NNT) of approximately 5 for ≥50% pain reduction, which was not meaningfully different from the NNT of 5.2 with 60 mg daily. 1
• Doses above 60 mg daily have not demonstrated additional benefit for fibromyalgia or generalized anxiety disorder. 1
• Doses exceeding 120 mg daily should be avoided because higher doses do not provide further therapeutic advantage and are associated with increased risk of adverse effects. 1

Common Pitfalls to Avoid

• Do not start at 20 mg as an initial therapeutic dose—this is subtherapeutic and may prolong the onset of benefit while still exposing patients to side effects like fatigue and nausea. 1
• Do not abruptly discontinue duloxetine—taper gradually over at least 2–4 weeks after more than 3 weeks of treatment to minimize withdrawal symptoms (dizziness, nausea, headache, irritability, paresthesias). 1, 2
• Do not combine with MAOIs—allow at least 14 days after stopping an MAOI before starting duloxetine, and at least 5 days after stopping duloxetine before starting an MAOI. 2
• Monitor blood pressure regularly, especially when combining with NSAIDs or in patients with cardiovascular disease, as duloxetine can cause modest increases in systolic and diastolic blood pressure. 1, 3

Monitoring During Initiation

• Assess for adverse effects at each follow-up visit, particularly nausea, dry mouth, headache, constipation, dizziness, and fatigue. 1
• Use standardized depression or pain scales to evaluate therapeutic response. 1
• Watch closely for mood changes, particularly in children, adolescents, and young adults during the first few months of treatment. 1